Take a look at this month’s industry headlines including an FDA approval for a vaccine protecting against six diseases, positive clinical trial results for bacteraemia and dengue vaccines and new funding for CRSIPR-based antimicrobials.
Browsing: Bacterial > MRSA
A first for clinical trials in the US as researchers from the University of California San Diego School of Medicine get US FDA approval to use intravenously-administered bacteriophage therapy in hopes of combatting resistant bacteria.
To round up 2018, we asked our Expert panel to choose their top papers from across the year. Here, you can discover the articles they selected and read about and the reasons why!
Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.
Researchers from Purdue University have reported that antimicrobial photodynamic therapy using a fluorescent analog of heme, could be an alternative for treating MRSA infections.
A recent study has revealed the metabolic pathway that bacteria use to survive in bone, which could potentially act as a target for the development of new antimicrobial compounds.
Antibiotic Research UK has raised concerns about staff shortages and over-occupancy in UK hospitals, stating this may be increasing the transmission of infections and putting patients in danger.
The WHO has released its first surveillance data on antibiotic resistance, revealing that it is widespread across both low-income and high-income countries.
Learn more about the top news stories of the week in our round-up, including the latest research on influenza, and new findings in MRSA infection.
Researchers have revealed that frequent recurrences of MRSA infection in mouse models may be due to bacterial toxins that ‘kill’ lymphatic muscle cells, effectively impairing their ability to pump lymphatic fluid to the lymph nodes.